Neoadjuvant Chemotherapy Therapy News This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
Chemoradiation Prevails in Cervical Cancer Trial
(MedPage Today) -- Reduced disease-free survival with neoadjuvant chemotherapy plus surgery (Source: MedPage Today OB/GYN)
Source: MedPage Today OB/GYN - June 15, 2018 Category: OBGYN Source Type: news
A 35-Year-Old Woman With a Change in HER2 Expression Following Neoadjuvant Chemotherapy for Invasive Breast Cancer
A 35-year-old woman noticed a mass in her right breast and underwent a diagnostic workup, including a mammogram that revealed a 2.4-cm mass and ultrasound that showed two adjacent masses, as well as enlarged axillary lymph nodes. (Source: CancerNetwork)
Source: CancerNetwork - June 15, 2018 Category: Cancer & Oncology Authors: Ericson Stoen, MD, Peter Kabos, MD, Kelly C. Borden, MD, Regina J. Brown, MD, Virginia F. Borges, MD, MMSc, Jennifer R. Diamond, MD Source Type: news
Race May Be Factor in Completion of Neoadjuvant Breast CA Chemo Race May Be Factor in Completion of Neoadjuvant Breast CA Chemo
White women with breast cancer are more likely to complete their neoadjuvant chemotherapy regimen than women of color, a U.S. study suggests.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 14, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Neoadjuvant CRT May Improve Survival in Pancreatic Cancer Neoadjuvant CRT May Improve Survival in Pancreatic Cancer
Results are preliminary, but patients who received neoadjuvant chemoradiation had better outcomes than did those who had immediate surgery.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 8, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Noninferiority of Neoadjuvant Chemo Cannot Be Confirmed in Ovarian Cancer Trial
Dave LevitanJun 6, 2018The noninferiority of neoadjuvant chemotherapy vs upfront surgery could not be confirmed with regard to overall survival in patients with ovarian, tubal, and peritoneal cancers. (Source: CancerNetwork)
Source: CancerNetwork - June 6, 2018 Category: Cancer & Oncology Authors: A Source Type: news
First study of neoadjuvant use of PARP inhibitor shows promise for early-stage, BRCA+ breast cancer patients
(University of Texas M. D. Anderson Cancer Center) In a small Phase II study of early-stage breast cancer patients with BRCA1/2 mutations, researchers at The University of Texas MD Anderson Cancer Center found that more than half of the women who took the PARP inhibitor talazoparib once daily prior to surgery had no evidence of disease at the time of surgery. If further validated in larger, confirmatory trials, the oral medication could replace chemotherapy for these patients. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 4, 2018 Category: Cancer & Oncology Source Type: news
Dose-Dense Chemo Shows Promise as Neoadjuvant Therapy in Bladder Cancer
A neoadjuvant dose-dense regimen was active and well tolerated in patients with muscle-invasive bladder cancer, allowing downstaging of most patients before radical cystectomy. (Source: CancerNetwork)
Source: CancerNetwork - May 11, 2018 Category: Cancer & Oncology Authors: Dave Levitan Tags: Bladder Cancer Genitourinary Cancers SiteTerms/www.cannabissciencetech.com/News Source Type: news
Nodal Response to Pre-Op Tx Tied to Survival in Esophageal Cancer
WEDNESDAY, May 2, 2018 -- For patients with locally advanced esophageal cancer, the status of lymph nodes following preoperative neoadjuvant chemotherapy or chemoradiation therapy determines survival, according to a study presented at the annual... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 2, 2018 Category: Pharmaceuticals Source Type: news
For patients with esophageal cancer, status of lymph nodes after preoperative therapy determines survival
(American Association for Thoracic Surgery) The status of lymph nodes rather than the status of the primary tumor following preoperative neoadjuvant chemotherapy or chemoradiation therapy is the most important factor that determines whether patients with locally advanced esophageal cancer will survive. The study presented at the AATS 98th Annual Meeting indicates that while preoperative chemotherapy and radiation therapy improve survival of patients with esophageal cancer, patients with malignant lymph nodes following therapy were less likely to survive than patients with no cancer in the lymph nodes. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 1, 2018 Category: Cancer & Oncology Source Type: news
Improved Rectal-Cancer Survival Seen With Adjuvant Chemotherapy Improved Rectal-Cancer Survival Seen With Adjuvant Chemotherapy
Adjuvant chemotherapy is associated with improved overall survival in patients with rectal cancer and pathological complete response after neoadjuvant chemotherapy and resection.Reuters Health Information (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 27, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Circulating Tumor Cell Count Predicts Early Breast Cancer Outcomes Circulating Tumor Cell Count Predicts Early Breast Cancer Outcomes
Circulating tumor cell (CTC) count independently predicts outcomes in women with early breast cancer treated with neoadjuvant chemotherapy, according to a meta-analysis.Reuters Health Information (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - April 24, 2018 Category: Pathology Tags: Hematology-Oncology News Source Type: news
TNT Is Viable for Locally Advanced Rectal Cancer
CR was 36% in the total neoadjuvant therapy cohort vs 21% in the cohort that received chemoradiotherapy with adjuvant chemotherapy. (Source: CancerNetwork)
Source: CancerNetwork - April 6, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Colorectal Cancer News Source Type: news
Total Neoadjuvant Approach Promising in Locally Advanced Rectal Cancer Total Neoadjuvant Approach Promising in Locally Advanced Rectal Cancer
Preoperative chemotherapy in combination with chemoradiation (total neoadjuvant therapy, or TNT) appears to have advantages over traditional approaches to treating locally advanced rectal cancer, according to new research.Reuters Health Information (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - April 3, 2018 Category: Surgery Tags: Hematology-Oncology News Source Type: news
Carboplatin in Neoadjuvant Chemo May Be Helpful in Triple-negative Breast Cancer Carboplatin in Neoadjuvant Chemo May Be Helpful in Triple-negative Breast Cancer
Carboplatin should be considered as a potential component of neoadjuvant chemotherapy for women with high-risk, triple-negative breast cancer, regardless of BRCA status, researchers suggest.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 19, 2018 Category: Consumer Health News Tags: Medscape Today News Source Type: news
Rethinking neoadjuvant chemotherapy for breast cancer
This BMJ analysis notes that neoadjuvant chemotherapy may not be beneficial to patients as increased pathological response of primary tumour does not translate into a survival benefit. It suggests that the widespread use of neoadjuvant chemotherapy should be reduced. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - January 12, 2018 Category: Consumer Health News Source Type: news